These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 20036877)

  • 1. Application and review of the separate ray model to investigate interaction effects.
    Straetemans R; Bijnens L
    Front Biosci (Elite Ed); 2010 Jan; 2(1):266-78. PubMed ID: 20036877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of methods for evaluating drug-drug interaction.
    Zhao L; Au JL; Wientjes MG
    Front Biosci (Elite Ed); 2010 Jan; 2(1):241-9. PubMed ID: 20036874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applying Emax model and bivariate thin plate splines to assess drug interactions.
    Kong M; Lee JJ
    Front Biosci (Elite Ed); 2010 Jan; 2(1):279-92. PubMed ID: 20036878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of methods for statistical analysis of combination studies.
    Donev AN
    Front Biosci (Elite Ed); 2010 Jan; 2(1):250-7. PubMed ID: 20036875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient experimental design and nonparametric modeling of drug interaction.
    Fang HB; Yu T; Tan M
    Front Biosci (Elite Ed); 2010 Jan; 2(1):258-65. PubMed ID: 20036876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emax model and interaction index for assessing drug interaction in combination studies.
    Lee JJ; Lin HY; Liu DD; Kong M
    Front Biosci (Elite Ed); 2010 Jan; 2(2):582-601. PubMed ID: 20036904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of synergy concepts of nonlinear blending and dose-reduction profiles.
    Peterson JJ
    Front Biosci (Schol Ed); 2010 Jan; 2(2):483-503. PubMed ID: 20036963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folic acid-enhanced synergy for the combination of trimetrexate plus the glycinamide ribonucleotide formyltransferase inhibitor 4-[2-(2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimidino[5,4,6][1,4]thiazin -6-yl)-(S)-ethyl]-2,5-thienoylamino-L-glutamic acid (AG2034): comparison across sensitive and resistant human tumor cell lines.
    Faessel HM; Slocum HK; Rustum YM; Greco WR
    Biochem Pharmacol; 1999 Mar; 57(5):567-77. PubMed ID: 9952321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and analysis of drug combination experiments.
    Straetemans R; O'Brien T; Wouters L; Van Dun J; Janicot M; Bijnens L; Burzykowski T; Aerts M
    Biom J; 2005 Jun; 47(3):299-308. PubMed ID: 16053254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction index and different methods for determining drug interaction in combination therapy.
    Lee JJ; Kong M; Ayers GD; Lotan R
    J Biopharm Stat; 2007; 17(3):461-80. PubMed ID: 17479394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thymidine and hypoxanthine protection patterns of the folic acid-enhanced synergies for combinations of trimetrexate plus a polyglutamylatable inhibitor of purine or thymidylate synthesis against human ileocecal HCT-8 cells.
    Faessel HM; Slocum HK; Rustum YM; Greco WR
    Int J Oncol; 2003 Aug; 23(2):401-9. PubMed ID: 12851689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experimental design and statistical analysis for three-drug combination studies.
    Fang HB; Chen X; Pei XY; Grant S; Tan M
    Stat Methods Med Res; 2017 Jun; 26(3):1261-1280. PubMed ID: 25744107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing in vitro combinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models.
    Meletiadis J; Verweij PE; TeDorsthorst DT; Meis JF; Mouton JW
    Med Mycol; 2005 Mar; 43(2):133-52. PubMed ID: 15832557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Super in vitro synergy between inhibitors of dihydrofolate reductase and inhibitors of other folate-requiring enzymes: the critical role of polyglutamylation.
    Faessel HM; Slocum HK; Jackson RC; Boritzki TJ; Rustum YM; Nair MG; Greco WR
    Cancer Res; 1998 Jul; 58(14):3036-50. PubMed ID: 9679969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-beta-D-arabinofuranosylcytosine.
    Greco WR; Park HS; Rustum YM
    Cancer Res; 1990 Sep; 50(17):5318-27. PubMed ID: 2386940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new nonlinear mixture response surface paradigm for the study of synergism: a three drug example.
    White DB; Slocum HK; Brun Y; Wrzosek C; Greco WR
    Curr Drug Metab; 2003 Oct; 4(5):399-409. PubMed ID: 14529372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A generalized response surface model with varying relative potency for assessing drug interaction.
    Kong M; Lee JJ
    Biometrics; 2006 Dec; 62(4):986-95. PubMed ID: 17156272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitation of folic acid enhancement of antifolate synergism.
    Gaumont Y; Kisliuk RL; Parsons JC; Greco WR
    Cancer Res; 1992 Apr; 52(8):2228-35. PubMed ID: 1532766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: analysis by a new response surface model.
    Meletiadis J; Stergiopoulou T; O'Shaughnessy EM; Peter J; Walsh TJ
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2053-64. PubMed ID: 17387150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and sample size for evaluating combinations of drugs of linear and loglinear dose-response curves.
    Fang HB; Tian GL; Li W; Tan M
    J Biopharm Stat; 2009 Jul; 19(4):625-40. PubMed ID: 20183430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.